Michael Gelband’s Definium Therapeutics DFTX Stock Holding History

Michael Gelband’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-104,915	Closed	-$1.98M	–	1876
2026 Q1	$1.98M	Buy	104,915 +85,967	+454%	+$1.46M	0.02%	786
2025 Q4	$254K	Buy	+18,948	New	+$234K	﹤0.01%	1348
2025 Q3	–	Sell	-17,877	Closed	-$116K	–	1842
2025 Q2	$116K	Buy	+17,877	New	+$118K	﹤0.01%	1348

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Michael Gelband's DFTX Position: Q2 2026 in Review

Michael Gelband sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 104,915 shares — an estimated $1.98M sold.

Michael Gelband first reported a position in DFTX in Q2 2025 and held it in 3 quarters. The position peaked at $1.98M in Q1 2026. 360 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Michael Gelband reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 104,915 Definium Therapeutics shares in Q2 2026, an estimated $1.98M.
Michael Gelband first reported a position in Definium Therapeutics in Q2 2025 and held it in 3 quarters.
Michael Gelband's Definium Therapeutics position peaked at $1.98M in Q1 2026.
360 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.